Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ResToP: Reinduction and Second TKI Stop with Ponatinib in CML with Molecular Response
2018-003281-14Phase 2Active
- Sponsor
- CRIS Cancer Foundation
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ponatinib in chronic myelogenous leukemia (CML), sponsored by CRIS Cancer Foundation. Primary endpoint: Maintenance of major molecular response at 52 weeks after ponatinib treatment-free remission. Started Nov 2019; status: active.
02
Drugs
ponatinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2018-003281-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003281-14.